Breast cancer in situ. From pre-malignant lesion of uncertain significance to well-defined non-invasive malignant lesion. The Danish Breast Cancer Cooperative Group Register 1977-2007 revisited

Acta Oncologica

Volumn 47, Issue 4, 2008, Pages 765-771

  Lænkholm, Anne Vibeke ^a   Jensen, Maj Britt ^b   Kroman, Niels ^c   Rank, Fritz ^c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b DBCG Registry   (Denmark)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CARCINOMA IN SITU; HEALTH CARE ORGANIZATION; HUMAN; MAMMOGRAPHY; MASTECTOMY; PRACTICE GUIDELINE; PRECANCER; PRIORITY JOURNAL; REVIEW; ARTICLE; BREAST TUMOR; DENMARK; DISEASE COURSE; FEMALE; PATHOLOGY; REGISTER;

BREAST NEOPLASMS; CARCINOMA IN SITU; DENMARK; DISEASE PROGRESSION; FEMALE; HUMANS; PRECANCEROUS CONDITIONS; REGISTRIES;

EID: 45149108869     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802043931     Document Type: Review

References (31)

1. Nielsen M, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy: A study of 83 women. Cancer 1984;54:612-5.
2. Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW Jr. Lobular carcinoma in situ of the breast: Detailed analysis of 99 patients with average follow-up of 24 years Am J Surg Pathol 1978;2:225-51.
3. Andersen JA. Lobular carcinoma in situ: A long-term followup in 52 cases. Acta Pathol Microbiol Scand Sect A 1974;82:519-33.
4. Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathological findings from the National Surgical Adjuvant Breast and Bowel Project. Twelve-year observations concerning lobular carcinoma in situ. Cancer 2004;100:238-44.
5. McCann J, Treasure P, Duffy T. Modelling the impact of detecting and treating carcinoma in situ in a breast screening programme. J Med Screen 2004;11:117-25.
6. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995;76:1197-200.
7. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathological findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17 Intraductal carcinoma. Cancer 1999;86:429-38.
8. Andersen JA. Lobular carcinoma in situ of the breast. An approach to rational treatment. Cancer 1977;39:2597-602.
9. Andersen JA. Lobular carcinoma in situ. A histological study of 52 cases. Acta Pathol Microbiol Scand A 1974;82:735-41.
10. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-708.
11. Graversen HP, Blichert-Toft M, Dyreborg U, Andersen JA. In situ carcinomas of the female breast. Incidence, clinical findings and DBCG proposals for management. Acta Oncol 1988;27:679-82.
12. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Ductal carcinoma in situ of the female breast. Short term results of a prospective nationwide study. Am J Surg Pathol 1992;16:1183-96.
13. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Lobular carcinoma in situ of the female breast. Short term results of a prospective nationwide study. Am J Surg Pathol 1993;17:14-21.
14. Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat 2000;62:197-210.
15. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of ductal carcinoma-in-situ. Lancet 1995;345:154-7.
16. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005;205:248-54.
17. Ottosen GL. Carcinoma in situ of the female breast. APMIS 2003;111(Suppl.108):1-67.
18. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, et al. Ductal carcinoma in situ-a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
19. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal cancinoma in situ of the breast. Am J Surg 2003;186:337-43.
20. Blichert-Toft M, Graversen HP, Andersen J, Dyreborg U, Green A. In situ carcinomas: A population based study on frequency, growth pattern and clinical aspects. World J Surg 1988;2:845-51.
21. Zafrani B, Fourguet A, Vilcoq JR, Legal M, Calle R. Conservative management of intraductal breast carcinoma with tumorectomy and radiation therapy. Cancer 1986;57:1299-301.
22. Perry N, Broeders M, Wolf C, Tornberg S, Holland R, Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis, 4th ed. European Communities; 2006.
23. Veronesi P, Intra M, Vento AR, Naninato P, Caldarella P, Paganelli G, et al. Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast 2005;14:520-2.
24. Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, et al. Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. European Commission Working Group on Breast Screening Pathology. Hum Pathol 1998;29:1056-62.
25. Breast Cancer Cooperative Group EORTC, Radiotherapy Group EORTC, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:3381-7.
26. Shelley Hwang E, Nyante SJ, Chen YY, Moore D, DeVries S, Korkola JE, et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004;100:2562-72.
27. Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M, et al. Pleomorphic lobular carcinoma of the breast: Role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005;207:1-13.
28. Kepple J, Henry-Tillman RS, Klimberg VS, Layeeque R, Siegel E, Westbrook K, et al. The receptor expression pattern in ductal carcinoma in situ predicts recurrence. Am J Surg 2006;192:68-71.
29. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001;4:400-18.
30. Barnes NLP, Khavari S, Boland GP, Cramer A, Knox F, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005;11:2163-8.
31. Njor SH, Olsen AH, Bellstrøm T, Dyreborg U, Bak M, Axelsson C, et al. Mammography screening in the county of Fyn. November 1993-December 1999. APMIS 2003, Suppl 110;111:1-33.